Filter By Product Search for
NTX
Loading...
Publication (1) NTX Full Name
N-terminal Telopeptide of Collagen Type-I
NTX Introduction
NTX, or N-terminal Telopeptide of Collagen Type-I, is a biomarker used to assess bone metabolism and bone resorption. It is a fragment of collagen type I, which is the main collagen found in the skeletal system, accounting for ∼90% of the organic chemical constituents of bone. Collagen type I provides strength and stability to bone tissue. During bone remodeling, which is a continuous process of bone formation and resorption, collagen type I is broken down by specialized cells called osteoclasts. NTX is released is released from bone into the blood and is subsequently drained by the kidney into the urine.
Measuring NTX levels in urine or blood samples can provide information about the rate of bone resorption, as higher NTX levels indicate increased bone turnover and resorption. It is commonly used in clinical settings to monitor bone health and assess the effectiveness of treatments for conditions such as osteoporosis. In addition, bone pain may be associated with elevated serum and urine NTX levels. It has been suggested that the dose of bisphosphonates can be adjusted to reduce bone marker levels and may be able to relieve bone pain. Bone resorption markers are considered superior to bone formation markers in predicting future changes in bone mass. Moreover, NTX levels are influenced by various factors, including age, gender, and certain medical conditions.
The measurement of NTX is typically performed using immunoassay techniques. Results are reported as a concentration of NTX in either nanograms per milliliter (ng/mL) for blood samples or nanomoles per millimole of creatinine (nmol/mmol Cr) for urine samples, which helps account for variations in urine concentration.
In conclusion, NTX level is an important parameter for evaluating bone resorption in bone morphometrics, and it is considered to be the most sensitive and specific indicator reflecting bone resorption status, which is of great significance for early prevention, diagnosis and differential diagnosis of metabolic bone diseases, and judgment of treatment regression.
Alternate Names for NTX
N-terminal Telopeptide of Collagen Type-I
N-terminal telopeptide
N-Telopeptide
Collagen Cross-Linked N-Telopeptide
NTX as a potential diagnostic and prognostic marker for bone metastasis in human cancers
Whether NTX can be used for diagnosis and prognostic prediction of bone metastases in human cancers has been controversial. Scientists explored the diagnostic and prognostic value of NTX for patients with cancer with bone metastases by conducting a meta-analysis of multiple publications.
The pooled analysis showed that NTX had a sensitivity of 77% and specificity of 80% for diagnosing bone metastasis in various cancer types. Combining NTX with other markers improved diagnostic efficacy, particularly in lung, breast, and prostate cancers in Asian populations. Regarding prognosis, high NTX levels were associated with a higher risk of poor overall survival in cancer patients with bone metastasis. The pooled hazard ratio (HR) for high versus low NTX levels was 2.12, indicating an increased risk of poor prognosis.
In conclusion, NTX, when combined with other markers, can serve as a useful biomarker for diagnosing and predicting the prognosis of bone metastasis in different cancers, including lung, breast, and prostate cancers.
